Summary
Johnson & Johnson's 2010 10-K report, filed on February 28, 2010, for the fiscal year ending January 3, 2010, details a company of substantial scale and diversified operations. As a large accelerated filer, JNJ operates across consumer health, pharmaceutical, and medical devices/diagnostics segments, indicating a robust business model with multiple revenue streams. The report emphasizes the company's commitment to research and development, vital for sustained innovation in its highly regulated industries. Investors can take note of JNJ's established market presence and the significant market value of its common stock, as well as its ongoing efforts to maintain compliance and transparency through its extensive filings.
Financial Highlights
55 data pointsBeta
Financial Statements
Beta
| Revenue | $61.90B |
| Cost of Revenue | $18.45B |
| Gross Profit | $43.45B |
| SG&A Expenses | $19.80B |
| Operating Income | $16.58B |
| Interest Expense | $451.00M |
| Net Income | $12.27B |
| EPS (Basic) | $4.45 |
| EPS (Diluted) | $4.40 |
| Shares Outstanding (Basic) | 2.76B |
| Shares Outstanding (Diluted) | 2.79B |
Key Highlights
- 1Johnson & Johnson is a large, well-established company operating in the healthcare sector, with its Common Stock registered on the New York Stock Exchange.
- 2The company operates across multiple segments, including consumer health, pharmaceuticals, and medical devices/diagnostics, offering diversification.
- 3Significant emphasis is placed on Research and Development (R&D), crucial for innovation and maintaining a competitive edge in its industries.
- 4The filing indicates a commitment to regulatory compliance and robust corporate governance, as evidenced by its status as a large accelerated filer and detailed reporting.
- 5The report incorporates by reference portions of the company's Annual Report to Shareholders and Proxy Statement, providing further detailed financial and operational information.
- 6JNJ maintains a significant market capitalization, with a reported aggregate market value of approximately $156 billion in common stock held by non-affiliates as of the last business day of the second fiscal quarter.
Frequently Asked Questions
Johnson & Johnson operates through diversified segments, which historically include consumer health, pharmaceuticals, and medical devices/diagnostics. This structure allows for multiple revenue streams and mitigates risks associated with any single market.
The company places a significant emphasis on Research and Development (R&D), which is critical for developing new products and therapies. This focus is essential for maintaining competitiveness and driving future growth in the dynamic healthcare industry.
As a large accelerated filer, Johnson & Johnson adheres to stringent SEC reporting requirements, demonstrating a commitment to transparency and investor communication. The company's filing includes standard disclosures regarding its business, risk factors, financial condition, and corporate governance.
Detailed financial information beyond what is presented in the 10-K is available through documents incorporated by reference, such as the company's Annual Report to Shareholders for the fiscal year 2009 and its Proxy Statement for the 2010 annual meeting.